Publication | Closed Access

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

Superiority TrialMedicineGynecologyCancer TreatmentPhase 2OncologyRadiation OncologyNovel TherapyMolecular OncologyOvarian CancerBevacizumab Versus Niraparib